Modulation of immune cell functions by the E3 ligase CBL-b

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Lutz Nicoladoni, Christina ^a,b   Wolf, Dominik ^c   Sopper, Sieghart ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Adoptive cell transfer; Autoimmunity; Cancer; Immunotherapy; Ubiquitination

Indexed keywords

B LYMPHOCYTE RECEPTOR; CBL PROTEIN; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEASOME; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; DENDRITIC CELL; DOWN REGULATION; ENDOCYTOSIS; GENE EXPRESSION; GENE MUTATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; UBIQUITINATION;

EID: 84923573868     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00058     Document Type: Article

References (164)

1. Lin AE, Mak TW. The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Current opinion in immunology (2007) 19(6):665-73. Epub 2007/11/27. doi: 10.1016/j.coi.2007.10.002. PubMed PMID: 18036806.
2. Moynagh PN. The roles of Pellino E3 ubiquitin ligases in immunity. Nature reviews Immunology (2014) 14(2):122-31. Epub 2014/01/22. doi: 10.1038/nri3599. PubMed PMID: 24445667.
3. Rajsbaum R, Garcia-Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3- ubiquitin ligase family in innate antiviral immunity. Journal of molecular biology (2014) 426(6):1265-84. Epub 2013/12/18. doi: 10.1016/j.jmb.2013.12.005. PubMed PMID: 24333484; PubMed Central PMCID: PMC3945521.
4. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 403(6766):211-6. Epub 2000/01/26. doi: 10.1038/35003228. PubMed PMID: 10646608.
5. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature (2000) 403(6766):216-20. Epub 2000/01/26. doi: 10.1038/35003235. PubMed PMID: 10646609.
6. Paolino M, Penninger JM. Cbl-b in T-cell activation. Seminars in immunopathology (2010) 32(2):137-48. Epub 2010/05/12. doi: 10.1007/s00281-010-0197-9. PubMed PMID: 20458601.
7. Wallner S, Gruber T, Baier G, Wolf D. Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions. Clinical & developmental immunology (2012) 2012:692639. Epub 2012/05/03. doi: 10.1155/2012/692639. PubMed PMID: 22550535; PubMed Central PMCID: PMC3328896.
8. Metzger MB, Pruneda JN, Klevit RE, Weissman AM. RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochimica et biophysica acta (2014) 1843(1):47-60. Epub 2013/06/12. doi: 10.1016/j.bbamcr.2013.05.026. PubMed PMID: 23747565.
9. Pickart CM. Mechanisms underlying ubiquitination. Annual review of biochemistry (2001) 70:503-33. Epub 2001/06/08. doi: 10.1146/annurev.biochem.70.1.503. PubMed PMID: 11395416.
10. van Wijk SJ, Timmers HT. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB journal: official publication of the Federation of American Societies for Experimental Biology (2010) 24(4):981-93. Epub 2009/11/27. doi: 10.1096/fj.09-136259. PubMed PMID: 19940261.
11. Haglund K, Di Fiore PP, Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends in biochemical sciences (2003) 28(11):598-603. Epub 2003/11/11. doi: 10.1016/j.tibs.2003.09.005. PubMed PMID: 14607090.
12. Weissman AM. Themes and variations on ubiquitylation. Nature reviews Molecular cell biology (2001) 2(3):169-78. Epub 2001/03/27. doi: 10.1038/35056563. PubMed PMID: 11265246.
13. Heissmeyer V, Rao A. E3 ligases in T cell anergy--turning immune responses into tolerance. Science's STKE: signal transduction knowledge environment (2004) 2004(241):pe29. Epub 2004/07/15. doi: 10.1126/stke.2412004pe29. PubMed PMID: 15252218.
14. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nature reviews Molecular cell biology (2002) 3(8):600-14. Epub 2002/08/03. doi: 10.1038/nrm883. PubMed PMID: 12154371.
15. Tanno H, Komada M. The ubiquitin code and its decoding machinery in the endocytic pathway. Journal of biochemistry (2013) 153(6):497-504. Epub 2013/04/09. doi: 10.1093/jb/mvt028. PubMed PMID: 23564907.
16. Nau MM, Lipkowitz S. Comparative genomic organization of the cbl genes. Gene (2003) 308:103-13. Epub 2003/04/25. PubMed PMID: 12711395.
17. Blake TJ, Shapiro M, Morse HC, 3rd, Langdon WY. The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. Oncogene (1991) 6(4):653-7. Epub 1991/04/01. PubMed PMID: 2030914.
18. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC, 3rd. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proceedings of the National Academy of Sciences of the United States of America (1989) 86(4):1168-72. Epub 1989/02/01. PubMed PMID: 2784003; PubMed Central PMCID: PMC286647.
19. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl protooncogene. Oncogene (1995) 10(12):2367-77. Epub 1995/06/15. PubMed PMID: 7784085.
20. Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger J, et al. cbl-3: a new mammalian cbl family protein. Oncogene (1999) 18(22):3365-75. Epub 1999/06/11. doi: 10.1038/sj.onc.1202753. PubMed PMID: 10362357.
21. Kim M, Tezuka T, Suziki Y, Sugano S, Hirai M, Yamamoto T. Molecular cloning and characterization of a novel cbl-family gene, cbl-c. Gene (1999) 239(1):145-54. Epub 1999/11/26. PubMed PMID: 10571044.
22. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, et al. Hakai, a c- Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nature cell biology (2002) 4(3):222-31. Epub 2002/02/12. doi: 10.1038/ncb758. PubMed PMID: 11836526.
23. Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E, et al. Cbl-3- deficient mice exhibit normal epithelial development. Molecular and cellular biology (2003) 23(21):7708-18. Epub 2003/10/16. PubMed PMID: 14560016; PubMed Central PMCID: PMC207562.
24. Liu YQ, Bai G, Zhang H, Su D, Tao DC, Yang Y, et al. Human RING finger protein ZNF645 is a novel testis-specific E3 ubiquitin ligase. Asian journal of andrology (2010) 12(5):658-66. Epub 2010/07/27. doi: 10.1038/aja.2010.54. PubMed PMID: 20657603; PubMed Central PMCID: PMC3739317.
25. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nature reviews Molecular cell biology (2005) 6(12):907-18. Epub 2005/10/18. doi: 10.1038/nrm1762. PubMed PMID: 16227975.
26. Mohapatra B, Ahmad G, Nadeau S, Zutshi N, An W, Scheffe S, et al. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochimica et biophysica acta (2013) 1833(1):122-39. Epub 2012/10/23. doi: 10.1016/j.bbamcr.2012.10.010. PubMed PMID: 23085373; PubMed Central PMCID: PMC3628764.
27. Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature (1999) 398(6722):84-90. Epub 1999/03/17. doi: 10.1038/18050. PubMed PMID: 10078535.
28. Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. Journal of leukocyte biology (2002) 71(5):753-63. Epub 2002/05/08. PubMed PMID: 11994499.
29. Sanjay A, Horne WC, Baron R. The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases. Science's STKE: signal transduction knowledge environment (2001) 2001(110):pe40. Epub 2001/11/29. doi: 10.1126/stke.2001.110.pe40. PubMed PMID: 11724969.
30. Thien CB, Walker F, Langdon WY. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Molecular cell (2001) 7(2):355-65. Epub 2001/03/10. PubMed PMID: 11239464.
31. Tsygankov AY, Teckchandani AM, Feshchenko EA, Swaminathan G. Beyond the RING: CBL proteins as multivalent adapters. Oncogene (2001) 20(44):6382-402. Epub 2001/10/19. doi: 10.1038/sj.onc.1204781. PubMed PMID: 11607840.
32. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (1999) 286(5438):309-12. Epub 1999/10/09. PubMed PMID: 10514377.
33. Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML, Jr., Miyake S, et al. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. The Journal of biological chemistry (2000) 275(1):367-77. Epub 2000/01/05. PubMed PMID: 10617627.
34. Ota S, Hazeki K, Rao N, Lupher ML, Jr., Andoniou CE, Druker B, et al. The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase. The Journal of biological chemistry (2000) 275(1):414-22. Epub 2000/01/05. PubMed PMID: 10617633.
35. Paolino M, Thien CB, Gruber T, Hinterleitner R, Baier G, Langdon WY, et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. Journal of immunology (2011) 186(4):2138-47. Epub 2011/01/21. doi: 10.4049/jimmunol.1003390. PubMed PMID: 21248250.
36. Bartkiewicz M, Houghton A, Baron R. Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl. A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor. The Journal of biological chemistry (1999) 274(43):30887-95. Epub 1999/10/16. PubMed PMID: 10521482.
37. Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S, Collins J, et al. Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c- Cbl and Cbl-b. Oncogene (2004) 23(42):7104-15. Epub 2004/07/27. doi: 10.1038/sj.onc.1207952. PubMed PMID: 15273720.
38. Liu J, DeYoung SM, Hwang JB, O'Leary EE, Saltiel AR. The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport. The Journal of biological chemistry (2003) 278(38):36754-62. Epub 2003/07/05. doi: 10.1074/jbc.M300664200. PubMed PMID: 12842890.
39. Loeser S, Penninger JM. Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b. Seminars in immunology (2007) 19(3):206-14. Epub 2007/03/30. doi: 10.1016/j.smim.2007.02.004. PubMed PMID: 17391982.
40. Li D, Gal I, Vermes C, Alegre ML, Chong AS, Chen L, et al. Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation. Journal of immunology (2004) 173(12):7135-9. Epub 2004/12/09. PubMed PMID: 15585834.
41. Zhang J, Bardos T, Li D, Gal I, Vermes C, Xu J, et al. Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. Journal of immunology (2002) 169(5):2236-40. Epub 2002/08/24. PubMed PMID: 12193687.
42. Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO molecular medicine (2011) 3(10):581-92. Epub 2011/07/09. doi: 10.1002/emmm.201100165. PubMed PMID: 21739608; PubMed Central PMCID: PMC3191120.
43. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435(7042):590-7. Epub 2005/06/03. doi: 10.1038/nature03724. PubMed PMID: 15931211.
44. Mathis D, Benoist C. Back to central tolerance. Immunity (2004) 20(5):509-16. Epub 2004/05/15. PubMed PMID: 15142520.
45. Borde M, Barrington RA, Heissmeyer V, Carroll MC, Rao A. Transcriptional basis of lymphocyte tolerance. Immunological reviews (2006) 210:105-19. Epub 2006/04/21. doi: 10.1111/j.0105-2896.2006.00370.x. PubMed PMID: 16623767.
46. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunological reviews (2006) 212:8-27. Epub 2006/08/15. doi: 10.1111/j.0105-2896.2006.00427.x. PubMed PMID: 16903903.
47. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature reviews Immunology (2006) 6(4):295-307. Epub 2006/03/25. doi: 10.1038/nri1806. PubMed PMID: 16557261.
48. Samelson LE. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annual review of immunology (2002) 20:371-94. Epub 2002/02/28. doi: 10.1146/annurev.immunol.20.092601.111357. PubMed PMID: 11861607.
49. Altman A, Isakov N, Baier G. Protein kinase Ctheta: a new essential superstar on the T-cell stage. Immunology today (2000) 21(11):567-73. Epub 2000/11/30. PubMed PMID: 11094261.
50. Marsland BJ, Kopf M. T-cell fate and function: PKC-theta and beyond. Trends in immunology (2008) 29(4):179-85. Epub 2008/03/11. doi: 10.1016/j.it.2008.01.005. PubMed PMID: 18328786.
51. Macian F. NFAT proteins: key regulators of T-cell development and function. Nature reviews Immunology (2005) 5(6):472-84. Epub 2005/06/02. doi: 10.1038/nri1632. PubMed PMID: 15928679.
52. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunological reviews (2011) 241(1):180-205. Epub 2011/04/15. doi: 10.1111/j.1600-065X.2011.01011.x. PubMed PMID: 21488898; PubMed Central PMCID: PMC3077803.
53. Sadegh-Nasseri S, Dalai SK, Korb Ferris LC, Mirshahidi S. Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology (2010) 129(1):1-7. Epub 2009/12/17. doi: 10.1111/j.1365-2567.2009.03206.x. PubMed PMID: 20002785; PubMed Central PMCID: PMC2807481.
54. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nature immunology (2001) 2(9):870-5. Epub 2001/08/30. doi: 10.1038/ni0901-870. PubMed PMID: 11526404.
55. Guo H, Qiao G, Ying H, Li Z, Zhao Y, Liang Y, et al. E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity. Cell reports (2012) 1(5):472-82. Epub 2012/07/06. doi: 10.1016/j.celrep.2012.04.008. PubMed PMID: 22763434; PubMed Central PMCID: PMC3387815.
56. Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 21(2):167-77. Epub 2004/08/17. doi: 10.1016/j.immuni.2004.07.013. PubMed PMID: 15308098.
57. Krawczyk CM, Jones RG, Atfield A, Bachmaier K, Arya S, Odermatt B, et al. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. Journal of immunology (2005) 174(3):1472-8. Epub 2005/01/22. PubMed PMID: 15661906.
58. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nature immunology (2002) 3(12):1192-9. Epub 2002/11/05. doi: 10.1038/ni855. PubMed PMID: 12415267.
59. Qiao G, Li Z, Molinero L, Alegre ML, Ying H, Sun Z, et al. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Molecular and cellular biology (2008) 28(7):2470-80. Epub 2008/01/30. doi: 10.1128/MCB.01505-07. PubMed PMID: 18227156; PubMed Central PMCID: PMC2268433.
60. Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G, et al. PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation. Science signaling (2009) 2(76):ra30. Epub 2009/06/25. doi: 10.1126/scisignal.2000046. PubMed PMID: 19549985.
61. Yang B, Gay DL, MacLeod MK, Cao X, Hala T, Sweezer EM, et al. Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells. Nature immunology (2008) 9(12):1356-63. Epub 2008/10/22. doi: 10.1038/ni.1670. PubMed PMID: 18931680; PubMed Central PMCID: PMC2935464.
62. Hanlon A, Jang S, Salgame P. Cbl-b differentially regulates activation-induced apoptosis in T helper 1 and T helper 2 cells. Immunology (2005) 116(4):507-12. Epub 2005/11/30. doi: 10.1111/j.1365-2567.2005.02252.x. PubMed PMID: 16313364; PubMed Central PMCID: PMC1802430.
63. Ou R, Zhang M, Huang L, Moskophidis D. Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection. Journal of virology (2008) 82(7):3353-68. Epub 2008/01/18. doi: 10.1128/JVI.01350-07. PubMed PMID: 18199651; PubMed Central PMCID: PMC2268476.
64. Parish IA, Rao S, Smyth GK, Juelich T, Denyer GS, Davey GM, et al. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood (2009) 113(19):4575-85. Epub 2009/02/11. doi: 10.1182/blood-2008-10-185223. PubMed PMID: 19204323; PubMed Central PMCID: PMC2680364.
65. Gronski MA, Boulter JM, Moskophidis D, Nguyen LT, Holmberg K, Elford AR, et al. TCR affinity and negative regulation limit autoimmunity. Nature medicine (2004) 10(11):1234-9. Epub 2004/10/07. doi: 10.1038/nm1114. PubMed PMID: 15467726.
66. Tran DQ. TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. Journal of molecular cell biology (2012) 4(1):29-37. Epub 2011/12/14. doi: 10.1093/jmcb/mjr033. PubMed PMID: 22158907.
67. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor betainduced inhibition of T helper type 1 differentiation. The Journal of experimental medicine (2002) 195(11):1499-505. Epub 2002/06/05. PubMed PMID: 12045248; PubMed Central PMCID: PMC2193549.
68. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 441(7090):235-8. Epub 2006/05/02. doi: 10.1038/nature04753. PubMed PMID: 16648838.
69. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 12(2):171-81. Epub 2000/03/14. PubMed PMID: 10714683.
70. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell (2005) 8(5):369-80. Epub 2005/11/16. doi: 10.1016/j.ccr.2005.10.012. PubMed PMID: 16286245.
71. Adams CO, Housley WJ, Bhowmick S, Cone RE, Rajan TV, Forouhar F, et al. Cbl-b(- /-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta. Journal of immunology (2010) 185(4):2051-8. Epub 2010/07/14. doi: 10.4049/jimmunol.1001171. PubMed PMID: 20624942.
72. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. The Journal of clinical investigation (2007) 117(4):1029-36. Epub 2007/03/17. doi: 10.1172/JCI29472. PubMed PMID: 17364027; PubMed Central PMCID: PMC1810570.
73. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. The Journal of experimental medicine (2007) 204(4):879-91. Epub 2007/04/04. doi: 10.1084/jem.20061699. PubMed PMID: 17403934; PubMed Central PMCID: PMC2118550.
74. Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, Wolf AM, et al. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunology and cell biology (2012) 90(1):130-4. Epub 2011/03/09. doi: 10.1038/icb.2011.11. PubMed PMID: 21383769.
75. Wohlfert EA, Callahan MK, Clark RB. Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. Journal of immunology (2004) 173(2):1059-65. Epub 2004/07/09. PubMed PMID: 15240694.
76. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. Journal of immunology (2006) 176(3):1316-20. Epub 2006/01/21. PubMed PMID: 16424156.
77. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. The Journal of experimental medicine (2003) 198(12):1875-86. Epub 2003/12/17. doi: 10.1084/jem.20030152. PubMed PMID: 14676299; PubMed Central PMCID: PMC2194145.
78. Harada Y, Harada Y, Elly C, Ying G, Paik JH, DePinho RA, et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. The Journal of experimental medicine (2010) 207(7):1381-91. Epub 2010/05/05. doi: 10.1084/jem.20100004. PubMed PMID: 20439537; PubMed Central PMCID: PMC2901074.
79. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. The Journal of experimental medicine (2008) 205(3):565-74. Epub 2008/02/20. doi: 10.1084/jem.20071477. PubMed PMID: 18283119; PubMed Central PMCID: PMC2275380.
80. Qiao G, Zhao Y, Li Z, Tang PQ, Langdon WY, Yang T, et al. T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells. Journal of immunology (2013) 191(2):632-9. Epub 2013/06/12. doi: 10.4049/jimmunol.1202068. PubMed PMID: 23749633; PubMed Central PMCID: PMC3702637.
81. Gruber T, Hinterleitner R, Hermann-Kleiter N, Meisel M, Kleiter I, Wang CM, et al. Cbl-b mediates TGFbeta sensitivity by downregulating inhibitory SMAD7 in primary T cells. Journal of molecular cell biology (2013) 5(6):358-68. Epub 2013/05/28. doi: 10.1093/jmcb/mjt017. PubMed PMID: 23709694.
82. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine (2012) 366(26):2455-65. Epub 2012/06/05. doi: 10.1056/NEJMoa1200694. PubMed PMID: 22658128; PubMed Central PMCID: PMC3563263.
83. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine (2012) 366(26):2443-54. Epub 2012/06/05. doi: 10.1056/NEJMoa1200690. PubMed PMID: 22658127; PubMed Central PMCID: PMC3544539.
84. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine (2010) 363(8):711-23. Epub 2010/06/08. doi: 10.1056/NEJMoa1003466. PubMed PMID: 20525992; PubMed Central PMCID: PMC3549297.
85. Qiao G, Ying H, Zhao Y, Liang Y, Guo H, Shen H, et al. E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation. Cell reports (2014) 6(4):709-23. Epub 2014/02/11. doi: 10.1016/j.celrep.2014.01.012. PubMed PMID: 24508458; PubMed Central PMCID: PMC3969736.
86. Oh SY, Park JU, Zheng T, Kim YK, Wu F, Cho SH, et al. Cbl-b regulates airway mucosal tolerance to aeroallergen. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology (2011) 41(3):434-42. Epub 2010/08/27. doi: 10.1111/j.1365-2222.2010.03593.x. PubMed PMID: 20738317; PubMed Central PMCID: PMC2994994.
87. Kaplan MH. Th9 cells: differentiation and disease. Immunological reviews (2013) 252(1):104-15. Epub 2013/02/15. doi: 10.1111/imr.12028. PubMed PMID: 23405898; PubMed Central PMCID: PMC3982928.
88. Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 506(7486):52-7. Epub 2014/01/31. doi: 10.1038/nature12988. PubMed PMID: 24476824; PubMed Central PMCID: PMC4052214.
89. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 507(7493):508-12. Epub 2014/02/21. doi: 10.1038/nature12998. PubMed PMID: 24553136.
90. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research (2005) 11(23):8326-31. Epub 2005/12/03. doi: 10.1158/1078-0432.CCR-05-1244. PubMed PMID: 16322292.
91. Oksvold MP, Dagger SA, Thien CB, Langdon WY. The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells. Molecular immunology (2008) 45(4):925-36. Epub 2007/09/18. doi: 10.1016/j.molimm.2007.08.002. PubMed PMID: 17868870.
92. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Critical reviews in immunology (2008) 28(2):109-26. Epub 2008/06/11. PubMed PMID: 18540827.
93. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, et al. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer research (2009) 69(15):6256-64. Epub 2009/07/23. doi: 10.1158/0008-5472.CAN-08-4516. PubMed PMID: 19622771; PubMed Central PMCID: PMC2732120.
94. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer research (2009) 69(22):8693-9. Epub 2009/10/29. doi: 10.1158/0008-5472.CAN-09-1456. PubMed PMID: 19861533; PubMed Central PMCID: PMC2779578.
95. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer research (2009) 69(10):4309-18. Epub 2009/05/14. doi: 10.1158/0008-5472.CAN-08-4102. PubMed PMID: 19435909; PubMed Central PMCID: PMC3084614.
96. Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nature reviews Immunology (2011) 11(10):658-71. Epub 2011/09/24. doi: 10.1038/nri3065. PubMed PMID: 21941294; PubMed Central PMCID: PMC3620656.
97. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28(4):571-80. Epub 2008/04/09. doi: 10.1016/j.immuni.2008.02.016. PubMed PMID: 18394936; PubMed Central PMCID: PMC3528789.
98. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry Part A: the journal of the International Society for Analytical Cytology (2013) 83(8):702-13. Epub 2013/05/08. doi: 10.1002/cyto.a.22302. PubMed PMID: 23650273.
99. Huang JY, Umehara H, Inoue H, Tabassam FH, Okazaki T, Kono T, et al. Differential interaction of Cbl with Grb2 and CrkL in CD2-mediated NK cell activation. Molecular immunology (2000) 37(17):1057-65. Epub 2001/06/12. PubMed PMID: 11399323.
100. Mallone R, Funaro A, Zubiaur M, Baj G, Ausiello CM, Tacchetti C, et al. Signaling through CD38 induces NK cell activation. International immunology (2001) 13(4):397-409. Epub 2001/04/03. PubMed PMID: 11282979.
101. McVicar DW, Burshtyn DN. Intracellular signaling by the killer immunoglobulin-like receptors and Ly49. Science's STKE: signal transduction knowledge environment (2001) 2001(75):re1. Epub 2001/12/26. doi: 10.1126/stke.2001.75.re1. PubMed PMID: 11752646.
102. Umehara H, Inoue H, Huang J, Kono T, Minami Y, Tanaka Y, et al. Role for adapter proteins in costimulatory signals of CD2 and IL-2 on NK cell activation. Molecular immunology (2002) 38(8):587-96. Epub 2002/01/17. PubMed PMID: 11792427.
103. Peterson ME, Long EO. Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk. Immunity (2008) 29(4):578-88. Epub 2008/10/07. doi: 10.1016/j.immuni.2008.07.014. PubMed PMID: 18835194; PubMed Central PMCID: PMC2639764.
104. Kim HS, Das A, Gross CC, Bryceson YT, Long EO. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity (2010) 32(2):175-86. Epub 2010/03/02. doi: 10.1016/j.immuni.2010.02.004. PubMed PMID: 20189481; PubMed Central PMCID: PMC2843589.
105. Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP- 76 promote synergistic activation of natural killer cells. Science signaling (2012) 5(232):ra49. Epub 2012/07/13. doi: 10.1126/scisignal.2002754. PubMed PMID: 22786724; PubMed Central PMCID: PMC3842037.
106. Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, et al. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. European journal of immunology (2014). Epub 2014/05/23. doi: 10.1002/eji.201444512. PubMed PMID: 24846123.
107. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Advances in cancer research (2008) 100:35-83. Epub 2008/07/16. doi: 10.1016/S0065-230X(08)00002- X. PubMed PMID: 18620092; PubMed Central PMCID: PMC3133732.
108. Qiao G, Lei M, Li Z, Sun Y, Minto A, Fu YX, et al. Negative regulation of CD40- mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. Journal of immunology (2007) 179(7):4473-9. Epub 2007/09/20. PubMed PMID: 17878343.
109. Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ, et al. Control of the B cellintrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity (2007) 26(5):567-78. Epub 2007/05/12. doi: 10.1016/j.immuni.2007.03.015. PubMed PMID: 17493844; PubMed Central PMCID: PMC1948079.
110. Yasuda T, Tezuka T, Maeda A, Inazu T, Yamanashi Y, Gu H, et al. Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B cells. The Journal of experimental medicine (2002) 196(1):51-63. Epub 2002/07/03. PubMed PMID: 12093870; PubMed Central PMCID: PMC2194016.
111. Yasuda T, Maeda A, Kurosaki M, Tezuka T, Hironaka K, Yamamoto T, et al. Cbl suppresses B cell receptor-mediated phospholipase C (PLC)-gamma2 activation by regulating B cell linker protein-PLC-gamma2 binding. The Journal of experimental medicine (2000) 191(4):641-50. Epub 2000/02/24. PubMed PMID: 10684856; PubMed Central PMCID: PMC2195830.
112. Sohn HW, Gu H, Pierce SK. Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk. The Journal of experimental medicine (2003) 197(11):1511-24. Epub 2003/05/29. doi: 10.1084/jem.20021686. PubMed PMID: 12771181; PubMed Central PMCID: PMC2193911.
113. Katkere B, Rosa S, Drake JR. The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation. The Journal of biological chemistry (2012) 287(20):16636-44. Epub 2012/03/28. doi: 10.1074/jbc.M112.357640. PubMed PMID: 22451666; PubMed Central PMCID: PMC3351345.
114. Niiro H, Jabbarzadeh-Tabrizi S, Kikushige Y, Shima T, Noda K, Ota S, et al. CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells. Blood (2012) 119(10):2263-73. Epub 2012/01/21. doi: 10.1182/blood-2011-04-351965. PubMed PMID: 22262777.
115. Veselits M, Tanaka A, Lipkowitz S, O'Neill S, Sciammas R, Finnegan A, et al. Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomes. PloS one (2014) 9(3):e89792. Epub 2014/03/22. doi: 10.1371/journal.pone.0089792. PubMed PMID: 24651487; PubMed Central PMCID: PMC3961229.
116. Steinman RM. Decisions about dendritic cells: past, present, and future. Annual review of immunology (2012) 30:1-22. Epub 2011/12/06. doi: 10.1146/annurev-immunol-100311-102839. PubMed PMID: 22136168.
117. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nature immunology (2003) 4(6):579-85. Epub 2003/05/06. doi: 10.1038/ni928. PubMed PMID: 12730692.
118. Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, et al. The E3 ligase c-Cbl regulates dendritic cell activation. EMBO reports (2011) 12(9):971-9. Epub 2011/07/30. doi: 10.1038/embor.2011.143. PubMed PMID: 21799517; PubMed Central PMCID: PMC3166462.
119. Wallner S, Lutz-Nicoladoni C, Tripp CH, Gastl G, Baier G, Penninger JM, et al. The role of the e3 ligase cbl-B in murine dendritic cells. PloS one (2013) 8(6):e65178. Epub 2013/06/14. doi: 10.1371/journal.pone.0065178. PubMed PMID: 23762309; PubMed Central PMCID: PMC3675148.
120. Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLRtriggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nature immunology (2010) 11(8):734-42. Epub 2010/07/20. doi: 10.1038/ni.1908. PubMed PMID: 20639876.
121. Arron JR, Vologodskaia M, Wong BR, Naramura M, Kim N, Gu H, et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. The Journal of biological chemistry (2001) 276(32):30011-7. Epub 2001/06/15. doi: 10.1074/jbc.M100414200. PubMed PMID: 11406619.
122. Hinterleitner R, Gruber T, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Tzankov A, Schuster M, et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PloS one (2012) 7(9):e44295. Epub 2012/09/11. doi: 10.1371/journal.pone.0044295. PubMed PMID: 22962608; PubMed Central PMCID: PMC3433477.
123. Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood (2003) 101(12):4862-9. Epub 2003/01/25. doi: 10.1182/blood-2002-10-3229. PubMed PMID: 12543858.
124. Akira S, Takeda K. Toll-like receptor signalling. Nature reviews Immunology (2004) 4(7):499-511. Epub 2004/07/02. doi: 10.1038/nri1391. PubMed PMID: 15229469.
125. Abe T, Hirasaka K, Kagawa S, Kohno S, Ochi A, Utsunomiya K, et al. Cbl-b is a critical regulator of macrophage activation associated with obesity-induced insulin resistance in mice. Diabetes (2013) 62(6):1957-69. Epub 2013/01/26. doi: 10.2337/db12-0677. PubMed PMID: 23349502; PubMed Central PMCID: PMC3661636.
126. Hirasaka K, Kohno S, Goto J, Furochi H, Mawatari K, Harada N, et al. Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes (2007) 56(10):2511-22. Epub 2007/07/03. doi: 10.2337/db06-1768. PubMed PMID: 17601987.
127. Bachmaier K, Toya S, Gao X, Triantafillou T, Garrean S, Park GY, et al. E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury. Nature medicine (2007) 13(8):920-6. Epub 2007/07/10. doi: 10.1038/nm1607. PubMed PMID: 17618294.
128. Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood (2007) 110(3):1022-4. Epub 2007/05/04. doi: 10.1182/blood-2006-12-061176. PubMed PMID: 17475912; PubMed Central PMCID: PMC1924768.
129. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2009) 27(36):6109-16. Epub 2009/11/11. doi: 10.1200/JCO.2009.23.7503. PubMed PMID: 19901108; PubMed Central PMCID: PMC3040009.
130. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood (2013) 122(14):2460-6. Epub 2013/08/21. doi: 10.1182/blood-2013-04-496448. PubMed PMID: 23958953.
131. Nadeau S, An W, Palermo N, Feng D, Ahmad G, Dong L, et al. Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins. Biochemistry and analytical biochemistry: current research (2012) Suppl 6(1). Epub 2012/07/30. doi: 10.4172/2161-1009.S6-001. PubMed PMID: 23997989; PubMed Central PMCID: PMC3757940.
132. Naramura M, Nandwani N, Gu H, Band V, Band H. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America (2010) 107(37):16274-9. Epub 2010/09/02. doi: 10.1073/pnas.1007575107. PubMed PMID: 20805496; PubMed Central PMCID: PMC2941297.
133. Kohno S, Ueji T, Abe T, Nakao R, Hirasaka K, Oarada M, et al. Rantes secreted from macrophages disturbs skeletal muscle regeneration after cardiotoxin injection in Cbl-bdeficient mice. Muscle & nerve (2011) 43(2):223-9. Epub 2011/01/22. doi: 10.1002/mus.21829. PubMed PMID: 21254087.
134. Yee NK, Hamerman JA. beta(2) integrins inhibit TLR responses by regulating NFkappaB pathway and p38 MAPK activation. European journal of immunology (2013) 43(3):779-92. Epub 2013/01/12. doi: 10.1002/eji.201242550. PubMed PMID: 23310953; PubMed Central PMCID: PMC3809911.
135. Choi EY, Orlova VV, Fagerholm SC, Nurmi SM, Zhang L, Ballantyne CM, et al. Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. Blood (2008) 111(7):3607-14. Epub 2008/02/02. doi: 10.1182/blood-2007-07-103077. PubMed PMID: 18239087; PubMed Central PMCID: PMC2275024.
136. Zhang J, Chiang YJ, Hodes RJ, Siraganian RP. Inactivation of c-Cbl or Cbl-b differentially affects signaling from the high affinity IgE receptor. Journal of immunology (2004) 173(3):1811-8. Epub 2004/07/22. PubMed PMID: 15265912.
137. Qu X, Sada K, Kyo S, Maeno K, Miah SM, Yamamura H. Negative regulation of FcepsilonRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b. Blood (2004) 103(5):1779-86. Epub 2003/11/08. doi: 10.1182/blood-2003-07-2260. PubMed PMID: 14604964.
138. Gustin SE, Thien CB, Langdon WY. Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-activated mast cells. Journal of immunology (2006) 177(9):5980-9. Epub 2006/10/24. PubMed PMID: 17056522.
139. Nakajima A, Sanjay A, Chiusaroli R, Adapala NS, Neff L, Itzsteink C, et al. Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research (2009) 24(7):1162-72. Epub 2009/03/05. doi: 10.1359/jbmr.090205. PubMed PMID: 19257814; PubMed Central PMCID: PMC2697622.
140. Adapala NS, Barbe MF, Tsygankov AY, Lorenzo JA, Sanjay A. Loss of Cbl-PI3K interaction enhances osteoclast survival due to p21-Ras mediated PI3K activation independent of Cbl-b. Journal of cellular biochemistry (2014) 115(7):1277-89. Epub 2014/01/29. doi: 10.1002/jcb.24779. PubMed PMID: 24470255.
141. Yokoi N, Komeda K, Wang HY, Yano H, Kitada K, Saitoh Y, et al. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nature genetics (2002) 31(4):391-4. Epub 2002/07/16. doi: 10.1038/ng927. PubMed PMID: 12118252.
142. Bergholdt R, Taxvig C, Eising S, Nerup J, Pociot F. CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. Journal of leukocyte biology (2005) 77(4):579-85. Epub 2005/01/05. doi: 10.1189/jlb.0904524. PubMed PMID: 15629882.
143. Doniz-Padilla L, Martinez-Jimenez V, Nino-Moreno P, Abud-Mendoza C, Hernandez- Castro B, Gonzalez-Amaro R, et al. Expression and function of Cbl-b in T cells from patients with systemic lupus erythematosus, and detection of the 2126 A/G Cblb gene polymorphism in the Mexican mestizo population. Lupus (2011) 20(6):628-35. Epub 2011/05/12. doi: 10.1177/0961203310394896. PubMed PMID: 21558139.
144. DeWan AT, Egan KB, Hellenbrand K, Sorrentino K, Pizzoferrato N, Walsh KM, et al. Whole-exome sequencing of a pedigree segregating asthma. BMC medical genetics (2012) 13:95. Epub 2012/10/11. doi: 10.1186/1471-2350-13-95. PubMed PMID: 23046476; PubMed Central PMCID: PMC3563469.
145. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cellmediated immune mechanisms in multiple sclerosis. Nature (2011) 476(7359):214-9. Epub 2011/08/13. doi: 10.1038/nature10251. PubMed PMID: 21833088; PubMed Central PMCID: PMC3182531.
146. Sanna S, Pitzalis M, Zoledziewska M, Zara I, Sidore C, Murru R, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature genetics (2010) 42(6):495-7. Epub 2010/05/11. doi: 10.1038/ng.584. PubMed PMID: 20453840; PubMed Central PMCID: PMC3786343.
147. International Multiple Sclerosis Genetics C, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. Risk alleles for multiple sclerosis identified by a genomewide study. The New England journal of medicine (2007) 357(9):851-62. Epub 2007/07/31. doi: 10.1056/NEJMoa073493. PubMed PMID: 17660530.
148. Banica LM, Besliu AN, Pistol GC, Stavaru C, Vlad V, Predeteanu D, et al. Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells. Int J Rheum Dis (2014). Epub 2014/10/30. doi: 10.1111/1756-185X.12509. PubMed PMID: 25351606.
149. Gomez-Martin D, Ibarra-Sanchez M, Romo-Tena J, Cruz-Ruiz J, Esparza-Lopez J, Galindo-Campos M, et al. Casitas B lineage lymphoma b is a key regulator of peripheral tolerance in systemic lupus erythematosus. Arthritis and rheumatism (2013) 65(4):1032-42. Epub 2013/01/03. doi: 10.1002/art.37833. PubMed PMID: 23280105.
150. Sturner KH, Borgmeyer U, Schulze C, Pless O, Martin R. A Multiple Sclerosis- Associated Variant of CBLB Links Genetic Risk with Type I IFN Function. Journal of immunology (2014) 193(9):4439-47. Epub 2014/09/28. doi: 10.4049/jimmunol.1303077. PubMed PMID: 25261476.
151. Zhou WB, Wang R, Deng YN, Ji XB, Huang GX, Xu YZ. Study of Cbl-b dynamics in peripheral blood lymphocytes isolated from patients with multiple sclerosis. Neuroscience letters (2008) 440(3):336-9. Epub 2008/06/21. doi: 10.1016/j.neulet.2008.05.089. PubMed PMID: 18565657.
152. Gruber T, Hinterleitner R, Pfeifhofer-Obermair C, Wolf D, Baier G. Engineering effective T-cell based antitumor immunity. Oncoimmunology (2013) 2(2):e22893. Epub 2013/03/26. doi: 10.4161/onci.22893. PubMed PMID: 23525844; PubMed Central PMCID: PMC3601162.
153. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert review of vaccines (2005) 4(5):699-710. Epub 2005/10/14. doi: 10.1586/14760584.4.5.699. PubMed PMID: 16221071.
154. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine (2010) 363(5):411-22. Epub 2010/09/08. doi: 10.1056/NEJMoa1001294. PubMed PMID: 20818862.
155. Powell DJ, Jr., Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of immunology (2006) 177(9):6527-39. Epub 2006/10/24. PubMed PMID: 17056585; PubMed Central PMCID: PMC2174602.
156. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature reviews Cancer (2008) 8(4):299-308. Epub 2008/03/21. doi: 10.1038/nrc2355. PubMed PMID: 18354418; PubMed Central PMCID: PMC2553205.
157. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annual review of immunology (2007) 25:243-65. Epub 2006/11/30. doi: 10.1146/annurev.immunol.25.022106.141527. PubMed PMID: 17129181.
158. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert opinion on biological therapy (2010) 10(4):547-62. Epub 2010/02/12. doi: 10.1517/14712591003614756. PubMed PMID: 20146634.
159. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-9. Epub 2006/09/02. doi: 10.1126/science.1129003. PubMed PMID: 16946036; PubMed Central PMCID: PMC2267026.
160. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Human molecular genetics (2011) 20(R1):R93-9. Epub 2011/03/19. doi: 10.1093/hmg/ddr102. PubMed PMID: 21415041; PubMed Central PMCID: PMC3095061.
161. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-9. Epub 2003/10/18. doi: 10.1126/science.1088547. PubMed PMID: 14564000.
162. Pilones KA, Aryankalayil J, Demaria S. Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clinical & developmental immunology (2012) 2012:720803. Epub 2012/11/03. doi: 10.1155/2012/720803. PubMed PMID: 23118781; PubMed Central PMCID: PMC3483734.
163. Huang JR, Tsai YC, Chang YJ, Wu JC, Hung JT, Lin KH, et al. alpha- Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. Journal of immunology (2014) 192(4):1972-81. Epub 2014/01/28. doi: 10.4049/jimmunol.1302623. PubMed PMID: 24465013.
164. Singh AK, Gaur P, Das SN. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions. Human immunology (2014) 75(3):250-60. Epub 2014/01/01. doi: 10.1016/j.humimm.2013.12.004. PubMed PMID: 24373798.